|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
2
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
3
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
4
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS
5














































.png)


